ClinicalTrials.gg
Not yet recruitingNCT07859813Updated Oct 6, 2026

A Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated Steatohepatitis

A Phase 2 interventional study of ARO-INHBE and Placebo in Metabolic Dysfunction-Associated Steatohepatitis, sponsored by Arrowhead Pharmaceuticals. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Arrowhead Pharmaceuticals · Phase 2, Interventional, and Treatment

Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study is designed to evaluate the safety and efficacy of ARO-INHBE in adults with suspected metabolic dysfunction-associated steatohepatitis (MASH).

02

Conditions studied

  • Metabolic Dysfunction-Associated Steatohepatitis

Browse trials for

Keywords

  • MASH
03

In context

Fatty Liver

663 studies on the registry are indexed under Fatty Liver; 185 are open to participants now.

This study's planned enrollment of 252 is above the median of 60 across 432 interventional studies indexed under Fatty Liver.

Browse Fatty Liver studies →

Lead sponsor

Arrowhead Pharmaceuticals is the lead sponsor of 50 studies on the registry; 9 are open to participants now.

Of its 24 completed or terminated interventional studies of FDA-regulated products, 12 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • between 30.0 to 50.0 kilograms (kg)/square meter (m\^2) (inclusive) with body weight ≤159 kg at Screening
  • Stable body weight
  • Participants on background glucagon-like peptide-1 (GLP-1) (or GLP-1/glucose-dependent insulinotropic polypeptide [GIP]) therapy must be on a stable dose for ≥6 months
  • Participants not on GLP-1 (or GLP-1/GIP) therapy must be treatment naïve or off therapy for ≥6 months.

Key Exclusion Criteria:

  • Clinical or laboratory signs of decompensated liver disease, history of esophageal varices, ascites, or hepatic encephalopathy, or history of cirrhosis on performed prior to Screening.
  • History or evidence of hepatic disease of non-metabolic dysfunction-associated steatotic liver disease (MASLD) etiology (viral hepatitis, alcoholic liver disease, primary biliary cholangitis [PBC], primary sclerosing cholangitis [PSC], Wilson's disease, alpha-1 antitrypsin [A1AT] deficiency, hemochromatosis, or hepatitis).
  • Type 1 diabetes mellitus (T1DM) or uncontrolled Type 2 diabetes mellitus (T2DM).
  • Use of non-GLP-1 receptor medications known to cause weight loss within 3 months prior to Screening.
  • Use of medications associated with weight gain (for example, tricyclic antidepressants, mirtazapine, paroxetine, atypical antipsychotics) unless on a stable dose ≥3 months prior to Screening with anticipated continuation on this dose throughout the trial.
  • end-organ disease.
  • Major surgery within 90 days of Screening.
  • Use of hepatocyte-targeted ribonucleic acid interference (RNAi) therapies within 6 months of Screening.
  • Insulin use within 6 months of Screening (except short-term peri-procedural/inpatient use).

Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
252 participants (estimated)

Study arms

  • Experimental
    ARO-INHBE Low Dose

    Participants will receive ARO-INHBE at a low dose on Days 1, 85, 169, and 253.

    Drug: ARO-INHBE

  • Placebo comparator
    Placebo for ARO-INHBE Low Dose

    Participants will receive placebo on Days 1, 85, 169, and 253.

    Drug: Placebo

  • Experimental
    ARO-INHBE High Dose (Schedule 1)

    Participants will receive ARO-INHBE at a high dose on Days 1, 85, 169, and 253.

    Drug: ARO-INHBE

  • Placebo comparator
    Placebo for ARO-INHBE High Dose (Schedule 1)

    Participants will receive placebo on Days 1, 85, 169, and 253.

    Drug: Placebo

  • Experimental
    ARO-INHBE High Dose (Schedule 2)

    Participants will receive ARO-INHBE at a high dose on Days 1, 85, and 169.

    Drug: ARO-INHBE

  • Experimental
    Placebo for ARO-INHBE High Dose (Schedule 2)

    Participants will receive placebo on Days 1, 85, and 169.

    Drug: Placebo

Interventions

  • DrugARO-INHBE

    Subcutaneous (SC) injection

  • DrugPlacebo

    SC injection

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Liver Fat Content (LFC) by Magnetic Resonance Imaging-proton Density Fat Fraction (MRI-PDFF) at Week 48

    Time frame: Baseline, Week 48

Secondary outcomes

  1. Percentage of Participants With Resolution of Steatohepatitis and No Worsening of Liver Fibrosis (Histology)

    Time frame: Week 48

  2. Percentage of Participants With Improvement in Liver Fibrosis by ≥1 Stage and No Worsening of Steatohepatitis (Histology)

    Time frame: Week 48

  3. Change From Baseline in Non-alcoholic Fatty Liver Disease Activity Score (NAS) Total Score and Individual Subscores (Steatosis, Hepatocyte Ballooning, and Lobular Inflammation) at Week 48

    Time frame: Baseline, Week 48

  4. Change From Baseline in Fibrosis Stage (Histology) at Week 48

    Time frame: Baseline, Week 48

  5. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: Baseline up to Week 48

  6. Change From Baseline in LFC by MRI-PDFF at Week 24

    Time frame: Baseline, Week 24

  7. Percentage of Participants With >30%, >50%, and >70% Reduction in LFC From Baseline by MRI-PDFF at Week 24 and Week 48

    Time frame: Week 24 and Week 48

  8. Change From Baseline Through Week 48 in Body Weight

    Time frame: Baseline through Week 48

  9. Change From Baseline Through Week 48 in Body Composition (Total Adipose Tissue [TAT], Visceral Adipose Tissue [VAT] Volume, and Total Lean Tissue [TLT]), by Whole-body Magnetic Resonance Imaging (WB-MRI)

    Time frame: Baseline through Week 48

  10. Change From Baseline Through Week 48 in Serum Activin E Protein

    Time frame: Baseline through Week 48

  11. Change From Baseline in Markers of Hepatic Steatosis at Week 48

    Time frame: Baseline through Week 48

  12. Change From Baseline in Markers of Inflammation at Week 48

    Time frame: Baseline through Week 48

  13. Change From Baseline in Markers of Fibrosis at Week 48

    Time frame: Baseline through Week 48

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Oct 2029, 37 months later.

Of 41 phase 2 interventional studies under Fatty Liver, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 36. This study's planned 37 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2026
First posted
Oct 6, 2026
StartEst.
Sep 2026
Primary completionEst.
Oct 2029
CompletionEst.
Oct 2029
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07859813
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Sep 2026 (estimated)
Primary completion
Oct 2029 (estimated)
Completion
Oct 2029 (estimated)
Last update
Oct 6, 2026

Study contacts

Medical Monitor
Contact
AROINHBE@arrowheadpharma.com
626-304-3400

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion